NIH Announces HIV Vaccine Clinical Trial Begins


A new preventative vaccine has been developed incorporating technology funded by the NIH since 2004. The trials will be conducted in the United States and South Africa.

NIH announces clinical trials are beginning in South Africa and the USA on a preventative HIV vaccine.  (Adobe Stock 406658254 by monticellllo)

NIH announces clinical trials are beginning in South Africa and the USA on a preventative HIV vaccine.

(Adobe Stock 406658254 by monticellllo)

The National Institutes of Health announced today that clinical trials are beginning in the United States and South Africa of a preventative HIV vaccine. The Phase 1 trial of a novel HIV vaccine candidate called VIR-1388 is called HVTN 142 and aims to assess the vaccine's safety and its ability to stimulate an HIV-specific immune response. VIR-1388 employs a cytomegalovirus (CMV) vector to deliver the vaccine material. The National Institute of Allergy and Infectious Diseases (NIAID) provides scientific and financial support for the study. CMV is a long-lasting virus, which may help maintain HIV vaccine material in the body over an extended period, potentially addressing issues of waning immunity observed in shorter-lived vaccine vectors. The first results are expected in late 2024, with an optional long-term substudy tracking participants for up to 3 years after their initial vaccine dose.

According to the announcement, “VIR-1388 is designed to instruct the immune system to produce T cells that can recognize HIV and signal an immune response to prevent the virus from establishing chronic infection. VIR-1388 uses a cytomegalovirus (CMV) vector, meaning a weakened version of CMV delivers the HIV vaccine material to the immune system without causing disease in the study participants. CMV has been present in much of the global population for centuries.” Many individuals who have CMV do not display any symptoms and may not even know they have the virus. CMV can persist in the body indefinitely, indicating that it may be able to effectively deliver and maintain HIV vaccine material for an extended period. This could potentially overcome the decreasing immunity often seen with shorter-lasting vaccine vectors.

HVTN 142 is being conducted at 6 locations in the United States and 4 in South Africa, involving the enrollment of 95 HIV-negative participants. These participants will be randomly assigned to 1 of 4 study groups, with 3 groups receiving different doses of the vaccine, while one group will receive a placebo. To enhance participant safety, the trial specifically recruits individuals already living with asymptomatic CMV.

Since 2004, NIAID has been instrumental in funding the discovery and development of the CMV vaccine vector. The current trial is being funded in collaboration with the Bill & Melinda Gates Foundation and Vir Biotechnology, headquartered in San Francisco. The study, designated as HVTN 142, is sponsored by Vir and is conducted through the NIAID-supported HIV Vaccine Trials Network (HVTN).

According to the announcement, "Additional information about the trial is available on under study identifier NCT05854381."

Related Videos
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
Christopher Reid, PhD  (Photo courtesy of Christopher Reid, PhD)
3D illustration: Candida auris   (Adobe Stock 635576411 By Niamh )
 MIS-C (Adobe Stock 350657530 by Bernard Chantal)
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
Related Content